A Prospective Study of Bone Marrow Hematopoietic and Mesenchymal Stem Cells in Type 1 Gaucher Disease Patients

Séverine Lecourt1,2,10, Enguerran Mouly3, Delphine Freida1,10, Audrey Cras1,2,10, Raphaël Ceccaldi4, Djazia Heraoui5, Christine Chomienne2, Jean-Pierre Marolleau6, Bertrand Arnulf3,7, Raphael Porcher8, Catherine Caillaud9, Valérie Vanneaux1,10, Nadia Belmatoug5, Jérôme Larghero1,2,10.

1 Assistance Publique-Hôpitaux de Paris, Hôpital Saint Louis, Unité de Thérapie Cellulaire et Centre d’Investigation Clinique en Biothérapies CIC-BT501, Paris, France, 2 INSERM UMR940, Institut Universitaire d’Hématologie, Hôpital Saint-Louis, Paris, France, 3 EA3963, Univ Paris Diderot, Sorbonne Paris Cité, Institut Universitaire d’Hématologie, Paris, France, 4 INSERM U944, Institut Universitaire d’Hématologie, Hôpital Saint-Louis, Paris, France, 5 Assistance Publique-Hôpitaux de Paris, Hôpital Beaugrenoble, Service de Médecine Interne, Centre de Référence pour les Maladies Lysosomales, Clichy, France, 6 Hôpital d’Amiens, Département d’Hématologie Clinique, Amiens, France, 7 Assistance Publique-Hôpitaux de Paris, Hôpital Saint Louis, Département d’Immunno-hématologie, Hôpital Saint-Louis, Paris, France, 8 Assistance Publique-Hôpitaux de Paris, Hôpital Saint Louis, Département de Biostatistiques et Information Médicale, Paris, France, 9 Laboratoire de Génétique Métabolique, Hôpital Cochin, Paris, France, 10 Univ Paris Diderot, Sorbonne Paris Cité, Paris, France

Abstract

Gaucher disease (GD) is an autosomal recessive disorder characterized by lysosomal glucocerebrosidase (GBA) deficiency leading to hematological and skeletal manifestations. Mechanisms underlying these symptoms have not yet been elucidated. In vivo, bone marrow (BM) mesenchymal stem cells (MSCs) have important role in the regulation of bone mass and in the support of hematopoiesis, thus representing potential candidate that could contribute to the disease. GBA deficiency may also directly impair hematopoietic stem/progenitors cells (HSPCs) intrinsic function and induce hematological defect. In order to evaluate the role of BM stem cells in GD pathophysiology, we prospectively analyzed BM-MSCs and HSPCs properties in a series of 10 patients with type 1 GD. GBA activity was decreased in all tested cell subtypes. GD-MSCs had an impaired growth potential, morphological and cell cycle abnormalities, decreased capacities to differentiate into osteoblasts. Moreover, GD-MSCs secreted soluble factors that stimulated osteoclasts resorbing activities. In vitro and in vivo primitive and mature hematopoiesis were similar between patients and controls. However, GD-MSCs had a lower hematopoietic supportive capacity than those from healthy donors. These data suggest that BM microenvironment is altered in GD and that MSCs are key components of the manifestations observed in GD.

Introduction

Gaucher Disease (GD) is a lysosomal storage disorder due to glucocerebrosidase (GBA, acid-β-glucosidase) deficiency [1]. Three clinical phenotypes are described based on the presence and degree of neurological involvement [2,3]. In type 1 GD, the accumulation of glucosylceramide in the lysosomal compartment of affected cells results in heterogeneous manifestations including visceral, hematological and skeletal involvement [2].

Skeletal manifestations of GBA deficiency mainly consist in Erlenmeyer flask deformity, bone marrow (BM) infiltration, osteopenia, avascular necrosis, infarction, fractures, lytic lesions and joint replacements. Pathophysiology of these manifestations remains poorly understood and hypotheses include inhibition of osteogenesis and/or stimulation of osteoclastogenesis by cytokines. Plasma levels of soluble factors involved in the regulation of osteoblasts and osteoclasts activity have thus been shown to be deregulated in GD, but the results reported in several studies were inconsistent and not correlated with clinical severity [3,4,5,6,7,8]. Hematological consequences of GBA deficiency mainly consists in anemia and thrombocytopenia [2,9,10]. Pathophysiology of hematological involvement in GD have been related to hypersplenism and hematopoietic impairment due to BM infiltration by Gaucher cells, but an intrinsic hematopoietic stem/progenitors cells (HSPCs) defect linked with GBA deficiency cannot be ruled out. Little is known regarding the functional integrity of GD patients BM microenvironment. Since BM mesenchymal stem cells (MSCs) are multipotent progenitors able to differentiate along various mesenchymal cell subtypes in vitro and in vivo and particularly into osteoblasts, we hypothesized that skeletal symptoms observed in GD may be, at least in part, the consequence of MSCs intrinsic abnormalities [11]. MSCs also support hematopoiesis through
extracellular matrix proteins expression and cytokines secretion. Therefore, hematological symptoms observed in GD may be the indirect consequence of MSCs abnormalities or/and HSPCs intrinsic alteration [12].

We actually previously described the role of GBA deficiency on MSCs and HSPCs functions in an in vitro chemical model of GD induced by conduritol b epoxide (CBE) treatment, which leads to a residual GBA activity of 1% compared to untreated cells and impaires stem cells function [13,14]. In a recent study, Campeau et al reported, in a type 1 GD patient, that MSCs displayed a low GBA activity and accumulated glucocerebrosidase [15]. MSCs phenotype and differentiation capabilities were found to be normal but an altered inflammatory secretome was observed. COX2 (cyclooxygenase-2), IL6 (Interleukin-6), PGE2 (Prostaglandin-E2) and CCL2 (Chemokine ligand-2) levels were increased compared to healthy donors MSCs, thus suggesting a contribution of MSCs in skeletal disease. These data have been recently confirmed in a mouse model of GD which displayed skeletal manifestations partly related to an impairment of BM MSCs properties [16].

In this prospective study, we analyzed MSCs and HSPCs functionality in a series of 10 type 1 GD patients.

Methods

Ethics statement

BM and blood samples were obtained from 10 type 1 GD patients after informed consent according to French authorities’ guidelines (ANSM, Agence Nationale de Sécurité du Médicament et des produits de Santé; clinical trial agreement #A90674-60 and registered at www.clinicaltrials.gov as NCT01439607). French authorities’ specifically approved this study and patients provided their written consent to participate. Healthy donors’ blood as well as BM samples were obtained after informed consent according to approved institutional guidelines (Assistance Publique-Hôpitaux de Paris, Paris, France).

Animal work: mice were housed in pathogen-free animal facility under conditions approved by the Animal Care and Use committee of the Institut Universitaire d’Hématologie, Paris, France that also approved this study. Mice were weekly examined for any signs of sickness, such as prostration, severe weight loss, all efforts were made to minimize suffering.

GBA activity measurement

GBA activity was measured in monocytes, lymphocytes, granulocytes, CD34+ cells and MSCs with PFB-FDGlu (5'-pentaffluorobenzoylaminofluorescein-di-β-D-glucoside) as substrate. Fluorescence was measured on the FL-1 emission channel by flow cytometry as previously described [16,17,18]. Results were calculated as previously described [16].

In vitro HSPCs studies

BM-CD34+ cells were isolated using the direct CD34 Progenitor Cell Isolation Kit (Miltenyi Biotec, Paris, France). Enumeration of BM-CD34+ cells from GD and controls was performed using the Stem-Kit reagents according to manufacturer’s protocol (Beckman Coulter, Roissy, France).

For CFUs assays, CD34+ cells were seeded in Methocult H4434 (Stem Cell Technologies, Grenoble, France) as previously described [13].

CD34+ cells were ex vivo expanded in IMDM medium supplemented with 10% fetal bovine serum, SCF (50 ng/mL), TPO (50 ng/mL), IL-3 (20 ng/mL) and Flt3-L (20 ng/mL) (Tebu-bio, Le Perray en Yvelines Cedex, France) during 12 days. Cells were counted at day 6 and 12.

Long Term CultureInitiating-Cell (LTC-IC) were plated onto healthy donors irradiated mesenchymal stem cells (MSCs) and incubated for 5 weeks. Weekly, the entire content of triplicate was harvested and plated in methylcellulose medium (Stem Cell Technologies). Colonies were counted at day 14.

Hematopoietic supportive capacity of MSCs derived from patients or healthy donors was evaluated by using limiting dilution assays for determination of LTC-IC frequency after 5 weeks, according to the Poisson statistical model (L-Calc™, StemCell Technologies).

NGS mice

Four- to 8-week-old NSG mice [20] (Jackson Laboratory, Bar Harbor, MI) were sublethally irradiated (2,25 Gy) before transplantation by retro-orbital injection of 1.10^6 CD34+ cells. Mice were anesthetized with 2,2,2-Tribromoethanol (Sigma-Aldrich) before intra femoral BM aspirate 7 weeks after transplantation.

MSCs culture and characterization

BM MSCs were isolated and expanded as previously described in Minimum Essential Medium–α (Invitrogen, Cergy Pontoise, France), supplemented with 10% Fetal Bovine Serum (HyClone, Logan, UT), Glutamax-1 (2 mM; Invitrogen), bFGF (1 ng/mL, R&D Systems, Lille, France) and antibiotic/antimycotic (1%, Invitrogen) [21]. Monoclonal antibodies conjugated with either fluorescein isothiocyanate or phycoerythrin and directed to CD90, CD45, CD73, CD80, CD13, CD29, CD105 or matched isotype control (all purchased from Becton Dickinson, Le Pont de Claix, France) were used for immunophenotyping. Data were acquired and analyzed on a five-parameter flow cytometer (FACScalibur, Becton Dickinson, San Jose, CA) with CellQuest-Pro software (Becton Dickinson).

CFU-F quantification

BM mononuclear cells were seeded at 1.10^4 cells/cm² in complete medium. At day 14, colony forming unit-fibroblasts (CFU-F) were fixed with methanol and stained with Giemsa. Colonies were quantified by microscopic examination.

Long term proliferation assays

MSCs were plated in triplicates in 6 well plates at the initial density of 5.10^4 cells/cm². Population doubling per passage was calculated as previously described [16].

Cell cycle analysis

Cells cycle analysis was assessed on MSCs at passage 3 to 4. Cells were trypsinized, fixed with 70% ethanol and stored for at least 24 h at −20°C. After ethanol removal, cells were washed twice with PBS and were incubated with staining solution (1 mg/mL RNase A [Roche Applied Science, Meylan, France] with 10 μg/mL propidium iodide [Sigma Aldrich] in PBS). Cell cycle analysis was performed by flow cytometry, and proportion of cells in the G0/G1, S and G2/M phase were calculated using Cell Quest Pro software (BD Biosciences).

Microtubules and nuclear fluorescent staining

For immunofluorescent staining, cells at passage 3 to 4 were grown on coverglass coated with fibronectin (1 mg/mL, Calbio-
Table 1. GD patients characteristics.

| Patient n° | Genotype         | Year, and age at diagnosis | Splenectomy | SMG | HMG | Hb (g/dL) | MCV (fl) | Platelet (×103/L) | WBC/mm³ | Chitotriosidase activity (nmol/h/ml) | Ferritinemia (µg/l) | Gamma-globulinemia (g/L) | Bone pain | Radiological manifestations (Xrays, MRI) | ERT (Year and age of start) | Time between last ERT and inclusion (days) |
|------------|------------------|-----------------------------|-------------|-----|-----|-----------|---------|-------------------|--------|-------------------------------|-------------------|--------------------------|-----------|----------------------------------------|------------------------|---------------------------------------------|
| 1          | N370S/ R406F     | 1983 (24)                   | +           | 13,2| 91  | 351      | 6200    | NA                | 112    | 13,9                         | +                  | pelvis infarct            |           | hip osteonecrosis, femurs and tibia     | 1997 (38)             | 335                                       |
| 2          | N370S/ R463C     | 1990 (12)                   | –           | 13  | 92,4| 202      | 7810    | 280               | 14     | 11,6                         | +                  | hip osteonecrosis           | 1997 (19) | infarct                                |                         | 2                                             |
| 3          | N370S/ R120W     | 1981 (34)                   | –           | 13,6| 87  | 104      | 4400    | 24 000            | 1501   | 13,4                         | –                  | femurs, tibia BI            | no treatment | no treatment                           |                         |                                               |
| 4          | N370S/ L324P     | 1992 (57)                   | +           | 13  | NA  | 51       | 2900    | 3930              | 1030   | 16,8 (monoclonal gammopathy) | –                  | Femur, tibia infarct       | 2009 (74) | 10                                       |                         |                                               |
| 5          | N370S/ L324P     | 1994 (61)                   | +           | 11,5| 94  | 77       | 3900    | 41 500            | 2235   | 10,4                         | –                  | right hip prothesis, left osteonecrosis | No treatment | no treatment                           |                         |                                               |
| 6          | N370S/ W494X     | 1997 (48)                   | +           | 14,9| 96  | 369      | 7100    | Deficit           | 579    | 8,4                          | +                  | Humerus, pelvis infarct      | 2005 (56) | 7                                        |                         |                                               |
| 7          | N370S/ G202R     | 1984 (34)                   | –           | 12,7| 93  | 174      | 4400    | 23 300            | 331    | 16,9 (monoclonal gammopathy) | +                  | hip prothesis, shoulder prothesis  | 2002 (52) | 260                                      |                         |                                               |
| 8          | N370S/ R120W     | 1969 (18)                   | +           | 13  | 92  | 303      | 7070    | 4900              | NA     | NA                           | +                  | humerus infarct, BI         | 2002 (51) | 294                                      |                         |                                               |
| 9          | N370S/ L444P     | 2010 (53)                   | +           | 14,7| 88  | 130      | 6400    | 13 200            | 807    | 13,4 (monoclonal gammopathy) | –                  | femurs infarct               | no treatment | no treatment                           |                         |                                               |
| 10         | N370S/ D218A     | 1998 (33)                   | –           | 16  | 85  | 127      | 5030    | 1700              | 307    | 7,5 (monoclonal gammopathy)   | –                  | femurs, tibia BI             | 04/01/2010 | 8                                        |                         |                                               |

SMG, splenomegaly; HMG, hepatomegaly; Hb, hemoglobin; MCV, mean corpuscular volume; WBC, white blood cell; MRI, magnetic resonance imaging; BI, bone infiltration; ERT, enzyme replacement therapy.
doi:10.1371/journal.pone.0069293.t001
chem, Meudon, France). After adhesion, cells were fixed for 15 min in 4% paraformaldehyde, permeabilized for 3 min with 0.1% Triton in PBS and washed three times in PBS. Cells were incubated with 3% BSA in PBS to block unspecific binding of the antibodies. Microtubules were labelled with rat anti-alpha tubulin antibodies (1/500, 30 min, Ab Serotec, Duesseldorf, Germany) revealed with goat anti-rat Cy3 (1/500, 45 min, Interchim, Montlucon, France). Hoechst (0.5 μg/mL) was used for nuclear staining. Slides were then mounted with Mowiol solution and observed using a Nikon fluorescence microscope. Nucleus size distribution was measured with the Image J software.

RT-qPCR

Total RNA was extracted (RNasey mini kit, Qiagen, Courtaboeuf, France) and cDNA was prepared with the High Capacity cDNA Reverse Transcription kit following the manufacturer’s instructions (Applied Biosystems, Courtaboeuf, France). HMBS (hydroxymethylbilane synthase) was used to normalize expression data and the 2^(-ΔΔCT) method was applied. Final results were expressed as the n-fold differences in target gene expression in GD MSCs compared with control MSCs. PCR were performed with Taqman gene expression inventoried probes (Runx2: Hs00231692_m1, HMBS: Hs00609297_m1) on 7900 real time PCR system (Applied Biosystems).

MSCs Osteogenic differentiation

For osteogenic differentiation, 70–80% confluent cultures at passage 4 to 5 were incubated in 6 wells micro-plates in osteogenic medium consisting of Dulbecco’s modified Eagle medium (DMEM, Invitrogen) with 4.5 g/L glucose supplemented with 10% FBS, 10^{-7}M dexamethasone, 50 μg/mL ascorbic acid and 3 mM inorganic phosphate (for alizarin red staining).

Alkaline phosphatase (ALP) activity was determined by the colorimetric conversion of p-nitrophenol from p-nitrophenylphosphate and normalized to total protein (BCA, Pierce) as previously described [16]. Results were expressed as nmol p-nitrophenol/ min/mg protein.

Osteoclast culture and bone resorption quantification

Peripheral blood mononuclear cells (PBMCs) were isolated by Ficoll gradient density and monocytes cells were purified using CD14 microbeads according to the manufacturer’s protocol (Miltenyi Biotec, Paris, France). Monocytes were plated on BD Biocoat Osteologic MultiTest Slides (BD Biosciences) at 8.10^4 cells/well in Minimum Essential Medium-α supplemented with 10% Fetal Bovine Serum, 1% antibiotic/antimycotic, 100 ng/mL M-CSF (monocyte colony stimulating factor), 100 ng/mL RANK-L (Receptor Activator for Nuclear Factor κ B Ligand) and 25 ng/mL TNF-α (Tumor Necrosis Factor alpha). Cells were fed twice weekly and at day 14, resorption pits were quantified using Von Kossa staining. Briefly, slides were fixed with 4% PFA and stained with 5% silver nitrate solution (Sigma Aldrich) for 30 minutes. Staining development was performed with 5% thiosulfate sodium (Sigma Aldrich). Wells were photographed and analyzed as percentage of resorbed areas according to the Technical Bulletin #444 from BD Biosciences.

In studies examining the effect of conditioned media (CM) from controls and GD patients MSCs, CM were harvested after 72 hours and kept frozen until resorption assay. After CD14 purification, 8.10^4 monocytes were cultured with CM from GD or control MSCs (1:1, volume/volume). CM was added at each media change.

Soluble factors production

MSCs supernatants from control and GD were used to quantitatively analyzed Dickkopf-related protein-1 (DKK-1), Stromal cell-derived factor-1 (SDF-1), osteopontin (OPN), osteoprotegerin (OPG), monocytes chemotactic protein-1 (MCP-1), interleukin-6 (IL-6) and interleukin-8 (IL-8) levels. Analyzes were performed on MSCs at passage 3 to 4 and supernatants were harvested 72 hours after trypsinisation. All testing were performed by enzyme-linked immunosorbent assay (ELISA) using commercially available kits (R&D Systems) according to the manufacturer’s instructions. Quantitative analysis of PGE2 was performed using a competitive binding technique according to the manufacturer’s protocol (R&D systems).
Differences between values were evaluated by Student’s t-tests. When normality tests or equal variance tests failed, Mann-Whitney tests were performed. A value of $P < 0.05$ was used to define statistical significance.

The box plots summarize the following statistical measures: medians are represented as horizontal bars (−), mean as plus (+) upper and lower quartiles are represented on the top and the bottom of the box, minimum and maximum data values are on the top and the bottom of the whiskers represented as dash (−) and atypical values are shown as circle (○). Number mentioned in results section represents median.

Results

Patients’ characteristics and GBA activity
Characteristics of the 10 GD patients prospectively included in this study are presented in Table 1. GD was confirmed by genotype analysis and by the detection of the enzymatic deficiency. Median age was 59.5 years (range 32–77 years). Severity scores presented in Table 1 are at study entry. Five patients displayed hematological disorders, four had monoclonal gammopathies, and bone abnormalities were observed in all patients. Seven patients received enzyme replacement therapy at the time of inclusion. None of the included patient was treated with B12 vitamin, and only one received iron therapy.

GBA activity was measured into sub-cellular fractions of blood, in BM-MSCs and in BM-CD34+ cells. Flow cytometry was chosen to assess GBA activity since it allows GBA activity measurement in sample cell subpopulation. Compared to controls, GD patients GBA activity was significantly decreased in all blood and BM cell sub-type (Figure 1). Various degrees of GBA deficiency was observed among cell population: mean GBA residual activity in GD patients monocytes was of 28% compared to controls (19% and 30% in ERT treated and untreated patients, respectively) and of 39% in HSPCs (36% and 41% in ERT treated and untreated patients, respectively). Interestingly, we observed that MSCs displayed the higher GBA activity among all cell subtype. Furthermore, GD patients MSCs were also found to have the highest GBA deficiency (21% of residual activity, 20% and 23% in ERT treated and untreated patients, respectively).

Hematopoiesis in GD patients
In order to study the impact of GBA deficiency on GD HSPCs, CD34+ cells were isolated from patients BM and compared with those of healthy donors. Consequences of GBA deficiency were evaluated on mature and primitive hematopoiesis. The percentage of BM-CD34+ cells was similar in GD patients and healthy donors (1.10% and 1.17% respectively, $P = 0.773$; Figure 2A). We next analyzed the CD34+ differentiation capacities and found that the median number of CFU-GM, BFU-E and CFU-Mk were similar between patients and controls (CFU-GM: 35.75 versus 24; BFU-E: 23.5 versus 14.75; CFU-Mk: 12.75 versus 11; $P = 0.140$, 0.068 and...
cells, isolated from both GD and healthy donor BM, were then ex-vivo expanded during 12 days in a SCF/TPO/IL-3/Flt3-L containing medium. The nucleated cells fold expansion was comparable in the two groups (mean ± SEM: 8.14 ± 1.27 versus 12.47 ± 1.49 at day 12 respectively, P = 0.9; Figure 2C), and no difference was observed regarding the phenotype of expanded cells (data not shown).

We also evaluated hematopoiesis in long-term culture and found that the number of colony-forming cells (CFCs) obtained weekly over a period of 5 weeks did not differ significantly between GD patients and controls (Figure 2D; P > 0.05), thus suggesting that in vitro CD34+ functionality was not impaired in the tested patients.

To determine the potential of HSPCs to restore hematopoiesis in vivo, GD and controls CD34+ cells were tested in xenograft experiments by injection into NSG mice. Engraftment was analyzed 7 weeks after transplantation. Relative number of colony-forming cells (CFCs) obtained weekly over a period of 5 weeks did not differ significantly between GD patients and controls (Figure 2D; P > 0.05), thus suggesting that in vitro CD34+ functionality was not impaired in the tested patients.

Because BM microenvironment regulates HSPCs biology, we aimed to study the potential role of MSCs on HSPCs functions. Healthy donors CD34+ cells were cultured on GD or healthy donors MSCs. Interestingly, we found that CFCs frequency was significantly decreased when GD-MSCs were used (1/890 (ranging from 1/943 to 1/600) versus 1/403 (ranging from 1/424 to 1/314) for control group, P = 0.023). Thus, GD-MSCs displayed lower hematopoietic supportive capacity than control-MSCs.

GBA deficiency impaired MSCs characteristics

MSCs progenitors from GD were analyzed for their ability to form fibroblastic colonies (CFU-F). CFU-F frequency did not significantly differ between GD and healthy donors cells (7 and 15 CFU-F respectively, P = 0.118, Fig. 3A). However, mean cell number per CFU-F was decreased in GD compared to healthy donors (2893 and 8000 cells/CFU-F respectively, P = 0.004).

The growth potential of MSCs from 10 GD patients was evaluated over the time and compared to controls (Ct, Figure 3B). Cell proliferation was heterogeneous for both GD and controls. However, MSCs from 6 GD patients (patients #4, 5, 7, 8, 9 and 10) had significantly lower proliferative capacity than control MSCs. Growth potential of MSCs from 4 other GD patients (patients #1, 2, 3 and 6) was similar to that of 2 controls. Lastly, none GD-MSCs proliferation reached the one observed for 3 controls. No correlation between clinical or biological patients characteristics and cell proliferation decrease could be found to

Figure 3. GD-MSCs characterization. (A) Histograms represents CFU-F quantification per 10^5 mononuclear cells (left panel) and mean cell number per CFU-F (right panel) obtained after culture of control (Ct) or GD BM samples (n = 10 and 7 for GD patients and controls respectively). (B) MSCs growth kinetics: cumulative population doubling (CPD) are shown for Ct and GD-MSCs (n = 5 and 10 respectively). (C) Cell cycle analysis was performed by flow cytometry on Ct and GD-MSCs. The percentage of cells in each phase of the cell cycle was determined by gating G0/G1, S and G2/M cells (n = 8 and 6 respectively). (D) Representative FSC/SSC flow cytometry profile of Ct and GD-MSCs. (E) Ct and GD-MSCs were stained with anti-alpha-tubulin (red) and with Hoechst for nuclear staining (blue). Typical non-round nuclei (angled panels) and large nuclei (arrows) were observed in GD-MSCs. Scale bars represent 50 µm. A and C: * indicates P<0.05.
explain the heterogeneous data obtained with GD-MSCs. GD-MSCs proliferation impairment was not related to an increased apoptosis or senescence (Figure S2A and B). MSCs phenotype was also similar between GD and controls (data not shown).

Cell cycle analysis was performed in order to investigate the abnormal expansion capacities of GD-MSCs. The relative number of cells in G0/G1 was significantly decreased in GD compared to healthy donors (78.9 and 89.6 respectively, \( P = 0.001 \), Figure 3C) whereas the G2/M-phase was increased (15.8 and 7.8 respectively, \( P = 0.001 \)). These data suggest that abnormal proliferation observed in GD-MSCs was related to cell cycle alteration.

The morphology of GD-MSCs was also altered as shown by forward scatter/side scatter (FSC/SSC) flow cytometric profile from 3 controls and 3 GD patients (Figure 3D). GD-MSCs volume (FSC) and cytoplasmic granularity (SSC) were increased, suggesting that glucosylceramide accumulation modified MSCs morphology. Moreover, immunofluorescent staining of cytoskeleton (microtubules) and nucleus (Hoechst) revealed the presence of 10% of cells with abnormal nuclear shape (non-round nuclei) among MSCs from GD whereas it was never observed in healthy donors MSCs (Figure 3E). We also found that nuclear size was increased in GD-MSCs as compared to healthy donors (278+/−97 \( \mu m^2 \) and 175+/−49 \( \mu m^2 \), respectively, \( P =0.002 \), n>150 cells from 3 healthy donors and 6 GD patients).

Bone remodeling balance in GD

Bone mass abnormalities observed in GD may be the consequence of an unbalance between bone formation by osteoblasts derived from MSCs, and bone resorption by osteoclasts of hematopoietic origin.

The \textit{in vitro} potential of MSCs to differentiate along the osteoblastic lineage was evaluated in GD-MSCs and compared to control MSCs. Phosphatase alkaline (ALP) activity was measured in basal condition, \textit{i.e.} in growth medium (D0), and after 14 days in osteogenic medium. At D0, no statistical difference was observed between GD and Ct (40.83 and 21.41 nmol/min/mg proteins respectively, \( P =0.302 \), Figure 4A). However, ALP activity was significantly decreased at D14 in GD-MSCs-derived osteoblasts compared to control (78.59 and 280.1 nmol/min/mg proteins respectively, \( P =0.037 \), Figure 4A). Because osteopontin (OPN) has been used as a marker of osteoblast function, we measured OPN level in supernatant after 14 days of culture in osteoblastic medium \cite{22}. Similarly to ALP activity, OPN secretion in MSCs-derived osteoblasts was significantly decreased in GD compared to healthy donors (6.02 and 37.11 pg/mL/10^4 cells respectively, \( P =0.017 \), Figure 4B). In addition, the expression of \( \text{RUNX2} \), the key transcription factor involved in osteogenic differentiation, was decreased in GD-MSCs compared to controls, at D0 and D14 (0.41 versus 0.92 respectively, \( P =0.001 \) at D0; 0.63 versus 1.79 respectively, \( P =0.001 \) at D14, Figure 4C). Taken together, these data revealed an impaired MSCs differentiation capacity in GD, suggesting that bone abnormalities observed in patients may be the consequence of a MSCs intrinsic defect.

\textit{In vivo}, bone mass is also regulated by osteoclasts that induce bone resorption. In order to evaluate osteoclasts function in GD, monocytes were cultured in osteoclastic medium during 14 days on calcium phosphate matrix and bone resorption areas were measured. No significant difference was observed between bone resorption areas from osteoclasts derived from GD or healthy donors CD14^+ cells (0.725 and 1.821\% of resorbed areas respectively, \( P =0.937 \), Fig. 4D, left panel). However, resorption areas were increased when monocyte-derived osteoclasts...
were cultured in the presence of GD-MSCs conditioned media compared to controls (12.1 and 8.8% of resorbed areas respectively, \(P=0.030\), Figure 4D, right panel). These data suggest that GD-MSCs secrete soluble factors that induce osteoclastic differentiation or activation. Bone mass modification observed during GD could thus be a consequence of MSCs intrinsic abnormalities, rather than a direct impairment of osteoclasts.

MSCs secretome

Alterations of osteoclasts function and of long-term hematopoiesis support described above in GD cells are likely related to MSCs deficiency. Mechanisms underlying this phenomenon may include secretome abnormalities. Campeau et al. reported that MSCs from one patient with type 1 GD had an altered secretome [15]. We also reported similar results in the \textit{in vitro} chemical model of GD, induced with CBE [14]. MSCs secretome was explored in 8 patients of our cohort (Figure 5).

Consistently with our previous study on MSCs treated with CBE, we found that MSCs from GD secrete significantly more Dickkopf-related protein-1 (DKK-1) than healthy donors (3226 and 976 pg/mL/10^4 cells respectively, \(P=0.020\)). Moreover, prostaglandin-E2 (PGE2) level was also increased in GD-MSCs supernatant (63.00 and 32.65 pg/mL/10^4 cells respectively, \(P=0.038\)). However, Monocytes chemotactic protein-1 (MCP-1) and Interleukin-8 (IL-8) levels, that were found to be increased in CBE treated MSCs and in Campeau’s study, were found similar between GD and controls (83.83 and 127.08 pg/mL/10^4 cells respectively for MCP-1, \(P=0.577\); 17.90 and 18.19 pg/mL/10^4 cells respectively for IL-8, \(P=0.525\)). IL-6 and stromal cell-derived factor-1 (SDF-1) levels were also similar between MSCs from GD and controls (418.62 and 918.37 pg/mL/10^4 cells respectively for IL-6, \(P=0.161\); 144.41 and 77.43 pg/mL/10^4 cells respectively for SDF-1, \(P=0.798\)).

**Discussion**

Mechanisms underlying bone abnormalities and hematological manifestation observed in GD are still a matter of debate. We hypothesized that GBA deficiency may be responsible for a deregulation of MSCs and/or HSPCs functional properties. Actually, MSCs are precursors of several cellular lineage including osteoblasts. They also play a central role in the BM niche by supporting HSPCs maintenance through the secretion of soluble factors and cell-cell interactions [11,12]. Thus, hematological manifestation in GD may be the consequence of an intrinsic abnormality or of an altered interaction with components of the BM niche.

We have previously shown, in a chemical model of GD obtained with CBE treatment, that GBA deficiency in MSCs lead to an increased secretion of several soluble factors that regulate bone metabolism and to an increased activation of resorbing osteoclasts [14]. Moreover, in the same \textit{in vitro} model, GBA deficiency in HSPCs impairs mature and primitive hematopoiesis [13]. In order to evaluate the consequences of GBA deficiency in...
patients BM cells, we designed a clinical trial in which 10 type 1 GD patients were prospectively included, and MSCs/HSPCs studied.

We first evaluated GBA activity in sub-cellular fractions from blood and BM using a flow cytometric approach. Interestingly, we found the highest GBA deficiency in MSCs with 21% of residual activity, suggesting that MSCs may be a key component of abnormalities observed in GD.

In our previous in vitro studies, cells were treated by 0.5 mM CBE. Such treatment induces a reduction of GBA activity to 1% of untreated cells activity, in both MSCs and in HSPCs [13,14]. In contrast with this chemical model, data collected in patients argues for a conserved in vitro and in vivo HSPCs function. These discrepancies may be explained by the GBA residual activity. The “critical threshold” hypothesis, proposed by Conzelmann and Sandhoff, was actually demonstrated in fibroblasts from patients with β-hexosaminidase-A or alysulfatase-A deficiency and in the J774 murine macrophage cell line treated by CBE [23,24,25]. In these models, it has been shown that an increased storage occurred when enzyme activity was reduced to 10-15% of the normal control levels. We analyzed HSPCs function in a group of 10 patients. Because of the rarity of the disease and of the prospective inclusion of the patients, our cohort was heterogeneous and only one patient displayed severe hematological disorders. Moreover, some patients were splenectomized, but we did not find correlation between splenectomy and in vitro results. The residual GBA activity observed in HSPCs patients (39% of controls, range 13 to 61%) may thus be sufficient to ensure HSPCs normal function. However, an intrinsic HSPCs abnormality in patients with lower GBA activity cannot be ruled out.

The hematopoietic functional deficit we observed after long-term culture of CD34+ cells on GD-MSCs suggests that microenvironment may contribute to the development of hematopoietic abnormalities in GD, consistently with previous studies [14,15]. Moreover, GBA residual activity in MSCs was found to be similar to the values determined in the “critical threshold” hypothesis.

The first consequence of GBA deficiency in GD-MSCs was the impairment of proliferation in short-term culture (as shown by mean cell number per CFU-F decrease) and over the time. Inhibition of proliferation was related to an increase in the G2/M phase of the cell cycle. Similarly to the CBE in vitro model, GD-MSCs were found to be bigger and exhibited abnormal shape and nucleus size. Lipids accumulation, and modification of the lipid rafts composition, have already been observed in CBE-treated macrophage and in fibroblasts from type 1 and 2 GD [26]. Lipid rafts are known to play a key role in cellular functions such as proliferation, apoptosis, adhesion, signal transduction and membrane trafficking and cytokinesis [27]. These data suggest that alteration of lipid metabolism in GD-MSCs may induce cytokinesis defect, cell structure abnormalities and cell proliferation decrease.

Since MSCs are osteoblasts precursors, we studied the ability of GD-MSCs to differentiate along the bone lineage. mRNA level of RUNX2, a key regulator of osteoblast differentiation, was decreased in GD-MSCs compared to healthy donors. In addition, ALP activity and osteopontin secretion level were found to be decreased in GD-MSCs. Bone mass homeostasis is also dependant on osteoclasts activity. It has been shown, in an in vitro CBE chemical model, that conditioned media from CBE-treated PBMC induced ex vivo osteoclastogenesis [28]. We quantified the resorbing potential of CD14+ derived osteoclasts cultured in osteoclastic media on calcium phosphate matrix. Our data revealed that the resorbing potential of CD14+ derived osteoclasts was not significantly different between GD and controls. However, osteoclasts activity was stimulated during culture in the presence of GD-MSCs conditioned media. These data demonstrated that GBA deficiency in GD-MSCs leads to an intrinsic decrease of osteogenic differentiation abilities and to an activation of osteoclasts resorbing activity through soluble factors secretion, thus likely contributing to the abnormal skeletal phenotype observed in GD patients. However, no difference was observed between treated or untreated patients, while it has been reported that ERT treatment may be responsible for inducing osteopenia in some patients [29].

In our previous study, we reported that CBE-treated MSCs secreted increased levels of IL-6, DKK-1, MCP-1, IL-8 and SDF-1. Campeau et al. found that COX2, IL-8, PGE2 and CCL2 levels were increased in a type 1 GD patient. In the present study, we confirmed that GD-MSCs secrete increased levels of DKK-1 and PGE2. DKK-1 overexpression has been shown to correlate with lytic lesions in multiple myeloma and to induce bone loss [30,31]. PGE2 also stimulate osteoclastogenesis [32,33]. DKK-1 and PGE2 may thus play a critical role in the development of bone lesions in GD.

These observations were strengthened by the increased resorption we observed when osteoclasts were cultured in the presence of GD-MSCs culture media.

The first type 1 GD mice models were either lethal or do not reproduce the human disease phenotype. More recently, two models, obtained by conditional deletion of the GBA1 gene, have been described. In the one reported by Enquist et al., mice phenotype was characterized by an involvement of hematopoietic organs [34]. The genetic disorder of the hematopoietic system was corrected by a hematopoietic stem cell gene therapy approach [35]. The other mice model associated hepatosplenomegaly, hematologic disease and skeletal complications [16]. Mice MSCs studies revealed that ex vivo proliferation was decreased and that osteopenia was related to a reduced osteoblast differentiation. We found similar abnormalities in our GD patient BM cells.

Thus, although the cohort of patients we analyzed was heterogeneous and does not allow to relate the in vitro findings with individual patient characteristics, our study provides direct evidence for an impairment of MSCs functions in type 1 GD. That MSCs are defective in type 1 GD opens the possibility of considering this cell type as a key contributor of bone defect observed in patients, and at a lesser extent of hematological manifestation.

Supporting Information

Figure S1 Phenotype of engrafted human cells in NSG mice. Human CD19+, CD33+, CD3+ and CD34+ expression was measured in mice BM 7 weeks after transplantation. Histograms represent mean+/– S.E.M. (TIF)

Figure S2 Apoptosis and senescence in MSCs from GD. (A) Flow cytometric detection of cell viability and apoptosis on MSCs from Ct and GD. Apoptotic cells were identified using Annexin-V staining and necrotic cells were identified using 7AAD dye. (B) Representative photograms of senescence assay based on β-galactosidase activity on MSCs from Ct and GD. Senescent cells appeared in blue (magnification x100). (TIF)

Author Contributions

Conceived and designed the experiments: SL JL. Performed the experiments: SL EM DF AC RC VV. Analyzed the data: SL EM DF AC RC C. Chomienne JP JM RP VV JL. Wrote the paper: SL JL. Included and followed the patients: DH NB BA. Performed genotype analysis: C. Caillaud.
References

1. Grabowski GA (2008) PhenoType, diagnosis, and treatment of Gaucher’s disease. Lancet 372: 1263–1271.
2. Charron J, Anderson HC, Kaplan P, Kolodny EH, Mistry P, et al. (2000) The Gaucher registry: demographics and disease characteristics of 1698 patients with Gaucher disease. Arch Intern Med 160: 2835–2843.
3. Allen MJ, Myer BJ, Keats JM, Relling MV, Korf BR, et al. (1997) Pro-inflammatory cytokines and the pathogenesis of Gaucher’s disease: increased release of interleukin-6 and interleukin-10. Qm 90: 19–25.
4. Barak Y, Acker M, Nisman B, Kalicikman I, Abrahamov A, et al. (1999) Cytokines in Gaucher’s disease. Eur Cytokine Netw 10: 205–210.
5. Giana G, Martini C, Leopaldi A, Tamaro G, Katouzi F, et al. (2003) Bone marker alterations in patients with type 1 Gaucher disease. Calcif Tissue Int 72: 185–189.
6. de Fost M, Out TA, de Wilde FA, Tijn EP, Pals ST, et al. (2000) Immunoglobulin and free light chain abnormalities in Gaucher disease type I: data from an adult cohort of 63 patients and review of the literature. Ann Hematol 87: 439–449.
7. Hollak CE, Evers L, Aerts JM, van Oers MH (1997) Elevated levels of M-CSF, sCD14 and IL-8 in type 1 Gaucher disease. Blood Cells Mol Dis 23: 201–212.
8. van Breemen MJ, de Fost M, Voerman JS, Laman JD, Boot RG, et al. (2007) Increased plasma macrophage inflammatory protein (MIP)-

tetralph and MIP-

beta levels in type 1 Gaucher disease. Biochim Biophys Acta 1772: 786–796.
9. Pastores GM, Weinreb NJ, Aerts H, Andria G, Cox TM, et al. (2004) Therapeutic goals in the treatment of Gaucher disease. Semin Hematol 41: 4–14.
10. Weinreb NJ, Charron J, Anderson HC, Kaplan P, Kolodny EH, et al. (2002) Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry. Am J Med 113: 112–119.
11. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, et al. (1999) Multilineage potential of adult human mesenchymal stem cells. Science 284: 143–147.
12. Majumdar MK, Keane-Moore M, Buyaner D, Hardy WB, Moorman MA, et al. (2003) Characterization and functionality of cell surface molecules on human mesenchymal stem cells. J Biomed Sci 10: 228–241.
13. Berger J, Lecourt S, Vanneau V, Rapatel C, Bousgard S, et al. (2010) Glucocerebrosidase deficiency dramatically impairs human bone marrow hematopoiesis in an in vitro model of Gaucher disease. Br J Haematol 150: 91–101.
14. Lecourt S, Vanneau V, Gros A, Freida D, Heraoui D, et al. (2011) Bone marrow microenvironment in an in vitro model of Gaucher Disease: consequences of glucocerebrosidase deficiency. Stem Cells Dev.
15. Campeau PM, Rafei M, Boivin MN, Sun Y, Grabowski GA, et al. (2009) Characterization of Gaucher disease bone marrow mesenchymal stem cells reveals an altered inflammatory secretome. Blood 114: 3181–3190.
16. Mistry PK, Liu J, Yang M, Notohl T, McGrath J, et al. (2010) Glucocerebrosidase gene-deficient mouse recapitulates Gaucher disease displaying cellular and molecular dysregulation beyond the macrophage. Proc Natl Acad Sci U S A 107: 19473–19478.
17. Lorincz M, Herzenberg LA, Duns Z, Barranger JA, Kerr WG (1997) Detection and isolation of gene-corrected cells in Gaucher disease via a fluorescence-activated cell sorter assay for lysosomal glucocerebrosidase activity. Blood 89: 3412–3420.
18. Rudensky B, Paz E, Alteros GV, Raveh D, Elorin D, et al. (2003) Fluorescent flow cytometric assay: a new diagnostic tool for measuring beta-glucocerebrosidase activity in Gaucher disease. Blood Cells Mol Dis 30: 97–99.
19. Lecourt S, Vanneau V, Leblanc T, Leroux G, Ternaux B, et al. (2010) Bone marrow microenvironment in Fanconi Anemia: a prospective functional study in a cohort of Fanconi Anemia patients. Stem Cells Dev.
20. Shultz LD, Lyons BL, Burzynski LM, Gotte B, Chen X, et al. (2003) Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hematopoietic stem cells. J Immunol 174: 6477–6489.
21. Arnulf B, Lecourt S, Soulier J, Ternaux B, Lacassagne MN, et al. (2007) Phenotypic and functional characterization of bone marrow mesenchymal stem cells derived from patients with multiple myeloma. Leukemia 21: 158–163.
22. Denhardt DT, Noda M, O’Regan AW, Pavlin DJ, Berman JS (2001) Osteoponin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival. J Clin Invest 107: 1053–1061.
23. Conzelmann E, Sandhoff K (1983) Partial enzyme deficiencies: residual activities and the development of neurological disorders. Dev Neurosci 6: 58–71.
24. Leineckel P, Michel S, Conzelmann E, Sandhoff K (1992) Quantitative correlation between the residual activity of beta-hexosaminidase A and arylsulfatase A and the severity of the resulting lysosomal storage disease. Hum Genet 88: 513–523.
25. Schueler UH, Kohler T, Kanies CR, Zirzow GC, Sandhoff K, et al. (2004) Correlation between enzyme activity and substrate storage in a cell culture model system for Gaucher disease. J Inherit Metab Dis 27: 649–658.
26. Hein JH, Duplock S, Hopwood JJ, Fuller M (2008) Lipid composition of microdomains is altered in a cell model of Gaucher disease. J Lipid Res 49: 122–128.
27. Nito H, Collins LL, Gould GW (2011) Vesicle trafficking and membrane remodelling in cytokinesis. Biochem J 437: 13–24.
28. Mucci JM, Scian R, De Frisco PN, Garcia FS, Ceci R, et al. Induction of osteoclastogenesis in an in vitro model of Gaucher disease is mediated by T cells via TNF-alpha. Gene 309: 51–59.
29. Rudzki Z, Okon K, Machaczka M, Racinska M, Papla B, et al. (2003) Enzyme replacement therapy reduces Gaucher cell burden but may accelerate osteopenia in patients with type I disease – a histological study. Eur J Haematol 70: 273–281.
30. Tian E, Zhu F, Walker R, Ramussen E, Ma Y, et al. (2003) The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 349: 2403–2404.
31. Qiang YW, Barlogie B, Rudikoff S, Shaughnessy JD Jr (2008) Dkk1-induced inhibition of Wnt-signaling in osteoblast differentiation is an underlying mechanism of bone loss in multiple myeloma. Bone 42: 669–680.
32. Take I, Kobayashi Y, Yamamoto Y, Tsuhoi H, Ochi T, et al. (2005) Prostaglandin E2 strongly inhibits human osteoclast formation. Endocrinology 146: 5204–5214.
33. Kobayashi Y, Take I, Yamashita T, Mizouguchi T, Ninomiya T, et al. (2005) Prostaglandin E2 receptors EP2 and EP4 are down-regulated during differentiation of mouse osteoclasts from their precursors. J Biol Chem 280: 24035–24042.
34. Enquist IB, Nilsson E, Ooka A, Mansson JE, Olsson K, et al. (2006) Effective cell and gene therapy in a murine model of Gaucher disease. Proc Natl Acad Sci U S A 103: 13019–13024.
35. Enquist IB, Nilsson E, Mansson JE, Ehinger M, Richter J, et al. (2009) Successful low-risk hematopoietic cell therapy in a mouse model of type 1 Gaucher disease. Stem Cells 27: 744–752.